Free Trial
LON:HZD

Horizon Discovery Group plc (HZD.L) (HZD) Share Price, News & Analysis

Horizon Discovery Group plc (HZD.L) logo
GBX 184.50 0.00 (0.00%)
(As of 12/23/2020)

About Horizon Discovery Group plc (HZD.L) Stock (LON:HZD)

Key Stats

Today's Range
184.50
184.75
50-Day Range
184.50
184.50
52-Week Range
88.40
200
Volume
50,000 shs
Average Volume
676,498 shs
Market Capitalization
£302.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.

Receive HZD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Discovery Group plc (HZD.L) and its competitors with MarketBeat's FREE daily newsletter.

HZD Stock News Headlines

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
AIBRF AIB Group plc
Watches Of Switzerland Group PLC (WOSG)
BG Group
See More Headlines

HZD Stock Analysis - Frequently Asked Questions

Horizon Discovery Group plc (HZD.L)'s stock was trading at GBX 184.50 at the beginning of 2024. Since then, HZD stock has increased by 0.0% and is now trading at GBX 184.50.
View the best growth stocks for 2024 here
.

Shares of HZD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Horizon Discovery Group plc (HZD.L) investors own include Flowgroup (FLOW), Faron Pharmaceuticals Oy (FARN), Bristol-Myers Squibb (BMY), Sorrento Therapeutics (SRNE), Autolus Therapeutics (AUTL), Barkerville Gold Mines Ltd. (BGM.V) (BGM) and Charter Communications (CHTR).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
416
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£54.63 million
Cash Flow
GBX 14.88 per share
Book Value
GBX 83.10 per share

Miscellaneous

Free Float
N/A
Market Cap
£302.98 million
Optionable
Not Optionable
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (LON:HZD) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners